Increased use of and confidence in antiretroviral PrEP for prevention of HIV found

More gay and bisexual men are using HIV pre-exposure prophylaxis (PrEP) with increased confidence in the benefits of HIV treatment for prevention, according to a UNSW study.

Significantly more gay and bisexual men are using the antiretroviral drug PrEP to prevent HIV infection, according to the latest report from the PrEPARE Project.

The national online survey of Australian gay and bisexual men found that 43% of gay and bisexual men had used PrEP in 2019, up from 24% in 2017. This substantial increase aligns with falling HIV infections among gay and bisexual men in many jurisdictions.

The PrEP users surveyed reported positive experiences of using the drug, with the majority reporting reduced concern about HIV and increased sexual pleasure as a result. They also reported fewer concerns about disclosing PrEP use to others.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search